Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Seguridad, tolerabilidad e inmunogenicidad de MenABCWY administrado en diferentes programas de dosificación en adolescentes sanos

25 de septiembre de 2026 actualizado por: GlaxoSmithKline

Un estudio de fase IIb, aleatorizado, observador ciego para describir la seguridad, la tolerabilidad y la inmunogenicidad de MenABCWY administrado en diferentes programas de dosificación en adolescentes sanos

The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.

Descripción general del estudio

Estado

Activo, no reclutando

Tipo de estudio

Intervencionista

Inscripción (Actual)

305

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Bramsche, Alemania, 49565
        • GSK Investigational Site
      • Herxheim, Alemania, 76863
        • GSK Investigational Site
      • Leipzig, Alemania, 16269
        • GSK Investigational Site
      • Mannheim, Alemania, 68309
        • GSK Investigational Site
      • Schweigen-Rechtenbach, Alemania, 76889
        • GSK Investigational Site
    • Bavaria
      • Schönau, Bavaria, Alemania, 83471
        • GSK Investigational Site
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35205
        • GSK Investigational Site
    • Arizona
      • Tucson, Arizona, Estados Unidos, 85745-2696
        • GSK Investigational Site
    • California
      • Ventura, California, Estados Unidos, 93003
        • GSK Investigational Site
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20016
        • GSK Investigational Site
    • Florida
      • Miami, Florida, Estados Unidos, 33173
        • GSK Investigational Site
      • Miami, Florida, Estados Unidos, 33156-7397
        • GSK Investigational Site
    • Georgia
      • Macon, Georgia, Estados Unidos, 31210
        • GSK Investigational Site
    • Indiana
      • Valparaiso, Indiana, Estados Unidos, 84088
        • GSK Investigational Site
    • Kentucky
      • Nicholasville, Kentucky, Estados Unidos, 40517
        • GSK Investigational Site
    • Louisiana
      • Haughton, Louisiana, Estados Unidos, 71037
        • GSK Investigational Site
    • Montana
      • Missoula, Montana, Estados Unidos, 59804
        • GSK Investigational Site
      • Missoula, Montana, Estados Unidos, 80216
        • GSK Investigational Site
    • Nebraska
      • Grand Island, Nebraska, Estados Unidos, 68803
        • GSK Investigational Site
      • Lincoln, Nebraska, Estados Unidos, 68510
        • GSK Investigational Site
      • Omaha, Nebraska, Estados Unidos, 68134
        • GSK Investigational Site
    • New York
      • Binghamton, New York, Estados Unidos, 13905-1118
        • GSK Investigational Site
      • Endwell, New York, Estados Unidos, 13850
        • GSK Investigational Site
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28226
        • GSK Investigational Site
    • Oregon
      • Gresham, Oregon, Estados Unidos, 97030
        • GSK Investigational Site
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29414-5834
        • GSK Investigational Site
    • Tennessee
      • Kingsport, Tennessee, Estados Unidos, 37660
        • GSK Investigational Site
    • Texas
      • Austin, Texas, Estados Unidos, 75024
        • GSK Investigational Site
      • Galveston, Texas, Estados Unidos, 77555 1115
        • GSK Investigational Site
    • Utah
      • Layton, Utah, Estados Unidos, 84037
        • GSK Investigational Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

11 años a 14 años (Niño)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Participants or/and participants' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.

  • Written or witnessed/thumb printed informed consent obtained from the participant/parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.

  • Written informed assent obtained from the participant (if applicable) prior to performing any study specific procedure.

  • A male or female between, and including, 11 and 14 years of age (i.e. 14 years + 364 days) at the time of the first vaccination.

  • Healthy participants as established by medical history, physical examination and clinical judgment of the investigator before entering into the study.

  • Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, hysterectomy, bilateral-salpingectomy or bilateral ovariectomy.

  • Female participants of childbearing potential may be enrolled in the study, if the participant:

    • has practiced adequate contraception for 30 days prior to first vaccination, and
    • has a negative pregnancy test* on the day of vaccination, and
    • has agreed to follow adequate contraception for 30 days before each of the 2 subsequent vaccinations and for 30 days after each vaccination * Urine samples for pregnancy testing will be collected from female participants of childbearing potential at Visit 1, Visit 3 and Visit 5 prior to the vaccination.

Exclusion Criteria:

Medical conditions

  • Current or previous, confirmed or suspected disease caused by N. meningitidis.

  • Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrolment.

  • Progressive, unstable or uncontrolled clinical conditions.

  • Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.

  • Any neuroinflammatory, congenital neurological conditions, encephalopathies, seizures. History of febrile convulsions should not lead to exclusion.

  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s)/product(s).

    • Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM197) and latex medicinal products or medical equipment whose use is foreseen in this study.
  • Abnormal function or modification of the immune system resulting from:

    • Autoimmune disorders or immunodeficiency syndromes.
    • Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to study vaccination. This will mean prednisone equivalent ≥20 mg/day for adult participants / ≥0.5 mg/kg/day with maximum 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed.
    • Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination.
    • Administration of long-acting immune-modifying drugs at any time during the study period.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.

Prior/Concomitant therapy

  • Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study vaccine(s)/product(s) during the period starting 30 days before the first dose of study vaccine(s)/product(s) (Day -29 to Day 1), or planned use during the study period.
  • Previous vaccination with any meningococcal (MenB or MenACWY) vaccine at any time prior to informed consent/ assent (as applicable) with the exception of meningococcal C (conjugated or polysaccharide) vaccination, if the last dose of MenC was received at ≤24 months of age.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of study vaccine/product or planned administration before the next blood sampling visit.
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first vaccine/product dose(s). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants / ≥0.5 mg/kg/day with maximum of 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or medical device).

Other exclusions

  • Child in care.
  • Pregnant or lactating female.
  • Female planning to become pregnant / planning to discontinue contraceptive precautions during the windows reported in the inclusion criterion.
  • History of /current chronic alcohol abuse and/or drug abuse as determined by the investigator.
  • Any study personnel or immediate dependants, family, or household members.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: ABCWY-24 Group

Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 721, 1 dose of Placebo at Day 1441.

Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.

Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.

Experimental: ABCWY-48 Group

Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 1441, 1 dose of Placebo at Day 721.

Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.

Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of participants with human serum bactericidal assay (hSBA) titers ≥ lower limit of quantitation (LLOQ) for each N. meningitidis serogroup B indicator strains
Periodo de tiempo: At Baseline (Day 1)

The immune response to 2 doses of the MenABCWY vaccine administered on a 0-, 24-month schedule, and a 0-, 48-month schedule is evaluated against each N. meningitidis serogroup B indicator strains.

At Baseline (Day 1)
Percentage of participants with hSBA titers ≥ LLOQ for each N. meningitidis serogroup B indicator strains
Periodo de tiempo: At 1 month after the second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)

The immune response to 2 doses of the MenABCWY vaccine administered on a 0-, 24-month schedule, and a 0-, 48-month schedule is evaluated against each N. meningitidis serogroup B indicator strains.

At 1 month after the second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)
Percentage of participants with solicited administration site events
Periodo de tiempo: During the 7 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)

The solicited administration site events include pain, redness, swelling and induration. Redness, swelling, and induration are summarized according to defined severity grading scales: None (0 to 24mm); Mild (25 to 50mm); Moderate (51 to 100mm); Severe (>100mm). Injection site pain is summarized according to "mild", "moderate" or "severe".

During the 7 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)
Percentage of participants with solicited systemic events
Periodo de tiempo: During the 7 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)

The solicited systemic events include fever, headache, nausea, myalgia, arthralgia and fatigue. Fever is defined as body temperature 38.0°C (100.4°F). The preferred location for measuring temperature in this study is the oral route. Solicited systemic events (except fever) are summarized according to "mild", "moderate" or "severe".

During the 7 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)
Percentage of participants with any unsolicited adverse events (AEs) including all serious adverse events (SAEs), AEs leading to withdrawal, adverse events of special interest (AESIs) and medically attended AEs
Periodo de tiempo: During the 30 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)

An unsolicited AE is an AE that was not included in a list of solicited events and must have been spontaneously communicated by a participant/participant's parent(s)/ Legally Acceptable Representative(s) who has signed the informed consent. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject or is an abnormal pregnancy outcome. AESIs are predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it. Medically attended AEs are symptoms or illnesses requiring a hospitalisation, or an emergency room visit, or visit to/by a health care provider.

During the 30 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)
Percentage of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs
Periodo de tiempo: During the 6 months (including the day of vaccination) following the first vaccination (Vaccine administered at Day 1)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject or is an abnormal pregnancy outcome. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it. Medically attended AEs are symptoms or illnesses requiring a hospitalisation, or an emergency room visit, or visit to/by a health care provider.

During the 6 months (including the day of vaccination) following the first vaccination (Vaccine administered at Day 1)
Percentage of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs
Periodo de tiempo: During the 6 months (including the day of vaccination) following the second vaccination (Vaccine administered at Day 721)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject or is an abnormal pregnancy outcome. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it. Medically attended AEs are symptoms or illnesses requiring a hospitalisation, or an emergency room visit, or visit to/by a health care provider.

During the 6 months (including the day of vaccination) following the second vaccination (Vaccine administered at Day 721)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of participants with hSBA titers ≥ LLOQ for N. meningitidis serogroups A, C, W and Y
Periodo de tiempo: At Baseline (Day 1), 1 month after the first dose of MenABCWY (Day 31) and 1 month after second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)

The immune response to 1 and 2 doses of the MenABCWY vaccine administered on a 0-, 24-month schedule, and a 0-, 48-month schedule is evaluated against N. meningitidis serogroups A, C, W and Y.

At Baseline (Day 1), 1 month after the first dose of MenABCWY (Day 31) and 1 month after second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)
Percentage of participants with hSBA titers ≥ LLOQ for each N. meningitidis serogroup B indicator strains and for serogroups A, C, W and Y
Periodo de tiempo: At 25 months after the second dose of MenABCWY (Day 1471 for the ABCWY-24 Group)

The antibody persistence at 25 months after the second dose of the MenABCWY vaccine administered on a 0-, 24-month schedule is evaluated against each N. meningitidis serogroup B indicator strains and serogroups A, C, W and Y.

At 25 months after the second dose of MenABCWY (Day 1471 for the ABCWY-24 Group)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

18 de noviembre de 2021

Finalización primaria (Estimado)

10 de marzo de 2027

Finalización del estudio (Estimado)

10 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

8 de octubre de 2021

Primero enviado que cumplió con los criterios de control de calidad

8 de octubre de 2021

Publicado por primera vez (Actual)

21 de octubre de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

25 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

IPD for this study will be made available via the Clinical Study Data Request site.

Marco de tiempo para compartir IPD

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Criterios de acceso compartido de IPD

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir